-
Improved survival in COVID‐19 related sepsis and ARDS treated with a unique “triple therapy” including therapeutic plasma exchange: A single center retrospective analysis J. Clin. Apher. (IF 1.5) Pub Date : 2024-02-26 Philip Keith, Rebecca Inez Caldino Bohn, Trung Nguyen, L. Keith Scott, Monty Richmond, Matthew Day, Carol Choe, Linda Perkins, Rebecca Burnside, Richard Pyke, Ben Rikard, Amanda Guffey, Arun Saini, H. J. Park, Joseph Carcillo
BackgroundThroughout the COVID‐19 pandemic, the mortality of critically ill patients remained high. Our group developed a treatment regimen targeting sepsis and ARDS which we labeled “triple therapy” consisting of (1) corticosteroids, (2) therapeutic plasma exchange (TPE), and (3) timely intubation with lung protective ventilation. Our propensity analysis assesses the impact of triple therapy on survival
-
Writing manuscripts for peer review J. Clin. Apher. (IF 1.5) Pub Date : 2024-02-23 Robert Weinstein
Little instruction in writing manuscripts for peer review is provided in nursing school or medical school. To relatively inexperienced would‐be authors, including junior physicians and allied health professionals, this avenue of professional communication may sometimes seem to be unattainable. Yet many of them are energetic and insightful, and have the potential to make contributions to the literature
-
Real-world evidence of heparin and citrate use in extracorporeal photopheresis: A hypothesis-generating data review of device settings and performance J. Clin. Apher. (IF 1.5) Pub Date : 2024-02-14 Laura S. Connelly-Smith, James Griffin, Albert T. Leung, Francesca Gennari
Extracorporeal photopheresis (ECP) is widely used for the treatment of cutaneous T-cell lymphoma, graft-vs-host disease, and other immune-related conditions. To avoid clotting during treatment, the ECP system used must be effectively primed with an anticoagulant. Heparin is the recommended anticoagulant for the THERAKOS CELLEX System, but acid citrate dextrose-A (ACDA) is often used. We compared system
-
Use of therapeutic plasma exchange to remove lipoprotein X in a patient with vanishing bile duct syndrome presenting with cholestasis, pseudohyponatremia, and hypercholesterolemia: A case report and review of literature J. Clin. Apher. (IF 1.5) Pub Date : 2024-02-09 Yujung Jung, Heather A. Nelson, David Ming-Hung Lin
Lipoprotein X (Lp-X) is an abnormal lipoprotein found in multiple disease conditions, including liver dysfunction and cholestasis. High Lp-X concentrations can interfere with some laboratory testing that may result in spurious results. The detection of Lp-X can be challenging, and there is currently a lack of consensus regarding the management of Lp-X other than treating the underlying disease.
-
Evaluation of a scoring system for vein suitability in platelet apheresis donors J. Clin. Apher. (IF 1.5) Pub Date : 2024-02-09 Shahida Noushad, Abhishekh Basavarajegowda, Esha Toora, Dibyajyoti Sahoo, K M Hari Priya
Donor vein assessment for the selection of good quality veins is crucial for a successful apheresis procedure. This study intends to find out the effectiveness of a vein assessment scoring tool (VST) used and found to be effective in selecting whole blood donors to reduce the difficulty in identifying good quality veins for the plateletpheresis procedure.
-
Safety and efficacy of peripheral blood stem cells collection in healthy children and pediatric patients with thalassemia major weighing 20 kg or less J. Clin. Apher. (IF 1.5) Pub Date : 2024-01-08 Libai Chen, Jianyun Wen, Xiaoxiao Xu, Jing Du, Yongsheng Ruan, Xiaoqin Feng, Juan Li, Yuelin He, Xuedong Wu
Peripheral blood stem cell (PBSC) collection in children poses challenges due to their small size, low body weight (BW), and unique pediatric physiology, especially among children weighing 20 kg (kg) or less.
-
A single center retrospective study: Comparison between centrifugal separation plasma exchange with ACD-A and membrane separation plasma exchange with heparin on acute liver failure and acute on chronic liver failure J. Clin. Apher. (IF 1.5) Pub Date : 2023-12-14 Xin-Fang Zhu, Jia-Qiang Li, Tian-Tian Liu, Yuan Wang, Yao Zhong, Qing-Mei Gao, Qi Zhang, Kang-Kang Yu, Chong Huang, Ning Li, Qing Lu, Wen-Hong Zhang, Ji-Ming Zhang, Rong Xia, Jian-Ming Zheng
The purpose of this retrospective study is to compare the efficacy and safety of the centrifugal separation therapeutic plasma exchange (TPE) using citrate anticoagulant (cTPEc) with membrane separation TPE using heparin anticoagulant (mTPEh) in liver failure patients. The patients treated by cTPEc were defined as cTPEc group and those treated by mTPEh were defined as mTPEh group, respectively. Clinical
-
MicroRNA and granulocyte-monocyte adsorption apheresis combotherapy after inadequate response to anti-TNF agents in ulcerative colitis J. Clin. Apher. (IF 1.5) Pub Date : 2023-12-06 Esteban Sáez-González, Inés Moret-Tatay, Guillermo Bastida, Mariam Aguas, Marisa Iborra, Pilar Nos, Belén Beltrán
Ulcerative colitis (UC) is an inflammatory bowel disease characterized by chronic inflammation of the gastrointestinal tract, affecting millions of individuals throughout the world, and producing an impaired health-related quality of life. Granulocyte and monocyte apheresis (GMA) is a therapeutic option for UC management to induce remission by selective removal of activated leukocytes from bloodstream
-
Validation of Nivestym compared to Neupogen: An NMDP analysis J. Clin. Apher. (IF 1.5) Pub Date : 2023-12-01 Joseph Maakaron, Katie Picotte, Kevin Tram, Ruth Bakken, Jason Oakes, Meghann Cody, John Miller, Steven M. Devine, Heather E. Stefanski
1 INTRODUCTION The Coronavirus Disease 2019 (COVID-19) pandemic in early 2020 resulted in multiple challenges for the NMDP. At the time, the Investigational New Drug (IND) protocol for peripheral blood stem cell (PBSC) mobilization was limited to the use of Neupogen (NP) (Amgen, CA), which created logistical problems on the supply side as it was difficult to rely on only one medication for mobilization
-
Therapeutic plasma exchange in refractory Susac's syndrome: A brief report J. Clin. Apher. (IF 1.5) Pub Date : 2023-11-21 Ryan D. Salazar, Krystol R. Weidner, Caroline R. Alquist
Susac's syndrome (SuS) is an autoimmune endotheliopathy that typically presents with the clinical triad of encephalopathy, hearing loss, and branch retinal artery occlusion. It has a wide range of possible presentations, and its pathogenesis remains uncertain. Fulminant and refractory cases are difficult to treat, and no standard treatment protocol has been established. However, therapeutic plasma
-
A retrospective study to investigate the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis with ulcerative colitis J. Clin. Apher. (IF 1.5) Pub Date : 2023-11-21 Ayumi Ito, Shun Murasugi, Maria Yonezawa, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige
Primary sclerosing cholangitis has a poor prognosis and can be accompanied by ulcerative colitis. Infection control is essential, so immunosuppressive drugs should ideally be preferably. Granulocyte and monocyte adsorptive apheresis does not suppress the immune system and is used to treat ulcerative colitis. Therefore, this study investigated the efficacy and safety of granulocyte and monocyte adsorptive
-
Fractionated plasma separation and adsorption integrated with continuous veno-venous hemofiltration in patients with acute liver failure: A single center experience from China J. Clin. Apher. (IF 1.5) Pub Date : 2023-11-20 Jianhua Dong, Li Huang, Chuan Li, Bian Wu, Xi Yang, Yongchun Ge
To evaluate the clinical efficacy and safety of fractionated plasma separation and adsorption integrated with continuous veno-venous hemofiltration (FPSA-CVVH) treatment in patients with acute liver failure (ALF).
-
Crude collection efficiency of CD34+ hematopoietic stem cell apheresis J. Clin. Apher. (IF 1.5) Pub Date : 2023-11-08 Yandy Marx Castillo-Aleman
Understanding the apheresis principles for harvesting hematopoietic stem cells (HSCs) is critical for performing efficient procedures. However, despite significant advances in estimating the collection efficiency (CE) of aphereses, many confounding factors still need to be addressed in the classical calculations. The CE values are unrestricted, and many procedures exhibit CEs of a given cell population
-
Vascular access for autologous peripheral blood stem cells collection by large volume leukapheresis: Single center experience J. Clin. Apher. (IF 1.5) Pub Date : 2023-11-08 Ines Bojanić, Greta Novosel, Marijana Lukač Baričević, Petar Škrnjug, Elena Horvat, Sanja Mazić, Josip Batinić, Sandra Bašić Kinda, Branka Golubić Ćepulić
Peripheral blood stem cell (PBSC) harvesting requires reliable and safe vascular access. In our institution, a change of practice was implemented and the central venous catheter (CVC) placement for all autologous PBSC collections was abandoned in favor of a careful evaluation of peripheral venous access (PVA) for each individual patient. The aim of this prospective study was to evaluate the rate of
-
Comorbidity in lipoprotein apheresis: Their role in the era of new lipid-lowering therapies J. Clin. Apher. (IF 1.5) Pub Date : 2023-10-19 Francesco Sbrana, Mascia Pianelli, Roberta Luciani, Federico Bigazzi, Carmen Corciulo, Andrea Ripoli, Tiziana Sampietro, Beatrice Dal Pino
Despite advance in pharmacotherapy of lipid disorders, lipoprotein apheresis (LA) plays a leading role in the management of severe hypercholesterolemia and in atherosclerosis prevention.
-
Therapeutic plasma exchange for mechanical red cell hemolysis: A case series J. Clin. Apher. (IF 1.5) Pub Date : 2023-10-18 Chloe E. Douglas, Taylor R. House, Larissa Yalon, Shina Menon
We present three cases of severely elevated plasma free hemoglobin (PFH) in pediatric patients on mechanical circulatory support devices at a tertiary pediatric care center. Due to severe levels of PFH in the setting of critical illness with the inability to pursue immediate mechanical device exchange, membrane filtration therapeutic plasma exchange (TPE) was performed, which resulted in a lowering
-
Hyperchloremic metabolic acidosis after plasma exchange in a patient with renal transplant rejection: A case report J. Clin. Apher. (IF 1.5) Pub Date : 2023-10-06 S.S.A. Simon, M.S. van Sandwijk, R.H.G. Olde Engberink
Therapeutic plasma exchange (TPE) is an effective treatment for several renal disorders, including renal transplant rejection. However, repeated plasma exchanges can result in various metabolic disturbances and complications. We present a 61-year old male with a medical history of type 2 diabetes, hypertension, successfully treated multiple myeloma, and a post-mortem kidney transplantation 7 months
-
Effectiveness of leukapheresis on early survival in acute myeloid leukemia: An observational propensity score matching cohort study J. Clin. Apher. (IF 1.5) Pub Date : 2023-10-03 Howon Lee, Jay Ho Han, Jae Kwon Kim, Jaeeun Yoo, Hyung Suk Cho, Jae-Ho Yoon, Byung Sik Cho, Hee-Je Kim, Jihyang Lim, Dong Wook Jekarl, Yonggoo Kim
The association between leukapheresis (LK) as a treatment option for hyperleukocytosis (HL) in patients with acute myeloid leukemia (AML) remains controversial.
-
Adsorptive cytapheresis in ulcerative colitis: A non-pharmacological therapeutic approach revisited J. Clin. Apher. (IF 1.5) Pub Date : 2023-10-03 Filippo Vernia, Angelo Viscido, Giovanni Latella
Adsorptive cytapheresis proves effective in a proportion of patients affected by ulcerative colitis. Relatively high cost and the need for apheresis facilities, prevented the widespread use of this therapeutic approach. More so following the introduction of anti-TNFα biosimilars which proved both effective and inexpensive. Anti-TNFα agents, however, are burdened by high rate of primary and secondary
-
Updates on the mobilization pipeline for hematopoietic stem cell collection J. Clin. Apher. (IF 1.5) Pub Date : 2023-09-25 Minh-Ha Tran, Muharrem Yunce
Hematopoetic Stem Cell Transplantation is a life saving procedure which requires mobilization of stem cells for apheresis procedure. In this review we aimed to examine mobilizing agents that are in use and under investigation. Apheresis practitioners who oversee stem cell collections should be familiar with the recent advances in mobilization agents to utilize most up-to-date information for better
-
Therapeutic plasma exchange decreases plasma anti-SARS-CoV-2 spike IgG without increasing the proximate incidence of COVID-19 J. Clin. Apher. (IF 1.5) Pub Date : 2023-09-14 Jensyn Cone Sullivan, Steven E. Conklin, Stephanie Conrad, Coby Horowitz, Mark Diethelm, Raymond Comenzo
Therapeutic plasma exchange (TPE) removes both pathologic and protective immunoglobulins (Ig). SARS-CoV-2 immunity is partially mediated by anti-SARS-CoV-2 spike antibodies (SAb), which impair viral host-cell invasion. Nonetheless, the systematic effect of TPE on SAb concentration and SARS-CoV-2 immunity is unknown.
-
Immunity in the balance: Fatal disseminated adenovirus infection in a patient undergoing plasma exchange and immunosuppressive chemotherapy for anti-glomerular basement membrane disease J. Clin. Apher. (IF 1.5) Pub Date : 2023-09-12 Jeremy W. Jacobs, Cristina A. Figueroa Villalba, Kristin Stendahl, Christopher A. Tormey, Elizabeth Abels
Anti-glomerular basement membrane (anti-GBM) disease (formerly known as Goodpasture's syndrome) is a rare autoinflammatory condition that affects the renal and/or pulmonary capillaries. The standard therapeutic regimen for anti-GBM disease involves therapeutic plasma exchange (TPE), cyclophosphamide, and corticosteroids to rapidly remove and inhibit autoantibody production and reduce organ inflammation
-
The first reported use of red blood cell exchange to treat hemoglobin Evans with secondary methemoglobinemia J. Clin. Apher. (IF 1.5) Pub Date : 2023-09-04 Lance A. Williams, Jill Adamski, Theresa N. Kinard, Natalie M. Ertz-Archambault, Qun Lu, Kristin Gray, Jennifer L. Herrick, Leon Su, Leslie Padrnos
This manuscript describes a novel approach for treating patients with long-term sequelae from hemoglobin Evans (Hb Evans). After instituting conservative therapies for approximately 2 years, our patient's symptoms continually worsened. Therefore, we performed red blood cell exchange (RBCx) to reduce his Hb Evans percentage and his co-existing elevation of methemoglobin. Our assumptions of clinical
-
The impact of the COVID-19 pandemic on source plasma donations J. Clin. Apher. (IF 1.5) Pub Date : 2023-08-22 Mischa L. Covington, Chesinta Voma, Sean R. Stowell
While the COVID-19 pandemic has impacted many aspects of healthcare, including routine blood donations, the impact of COVID-19 on the donation of source plasma critical to many aspects of patient care, including apheresis procedures, has been more difficult to define. As production of plasma-derived medicinal products (PDMPs) can take up to a year, shortages in source plasma donations may not be immediately
-
Baseline inflammation indexes and neutrophil-to-LDH ratio for prediction of the first mobilization failure without plerixafor-based regimens in multiple myeloma and lymphoma patients: A single-center retrospective study J. Clin. Apher. (IF 1.5) Pub Date : 2023-08-14 Ahmet Burak Dirim, Tarik Onur Tiryaki, Soner Altin, Sevgi Kalayoglu Besisik, Ipek Yonal Hindilerden, Meliha Nalcaci
Many factors were identified for mobilization failure (MF) in autologous hematopoietic stem-cell transplantation. To our knowledge, this is the first study to investigate the efficacy of baseline inflammation indexes and neutrophil-to-lactate dehydrogenase (LDH) ratio to predict MF in multiple myeloma (MM) and lymphoma.
-
Francis S. Morrison MD—Tribute to an apheresis leader J. Clin. Apher. (IF 1.5) Pub Date : 2023-08-10 Walter Linz, James T. Thigpen, Ronald G. Strauss
Francis S. Morrison MD was among the early developers and promoters of the American Society for Apheresis (ASFA). His work was pivotal in creating a lasting institutional structure from which American apheresis medical practice would develop decades after his death. Francis Morrison is honored each year at the ASFA annual meeting as ASFA awards the Francis S. Morrison MD Memorial Award Lecture to an
-
Navigating the neutropenic abyss with granulocyte transfusions: Retrospective single-center analysis of effectiveness and safety in India J. Clin. Apher. (IF 1.5) Pub Date : 2023-08-10 Priti Desai, Anisha Navkudkar, Bhausaheb Bagal, Chetan Dhamne, Hasmukh Jain, Manju Sengar, Girish Chinnaswamy, Lingaraj Nayak
Hemato-oncologic patients receiving intensive chemotherapy may develop severe neutropenia and serious bacterial and/or fungal infections. Granulocyte transfusions (GTs) may be beneficial as a bridging therapy in hemato-oncologic patients with febrile neutropenia.
-
In hospitalized patients undergoing therapeutic plasma exchange, major bleeding prevalence depends on the bleeding definition: An analysis of The Recipient Epidemiology and Donor Evaluation Study-III J. Clin. Apher. (IF 1.5) Pub Date : 2023-08-07 Alexandre Soares Ferreira Junior, Morgana Pinheiro Maux Lessa, Kate Sanborn, Maragatha Kuchibhatla, Matthew S Karafin, Oluwatoyosi A. Onwuemene
Major bleeding in patients undergoing therapeutic plasma exchange (TPE) has been studied in large databases; but without standardizing bleeding definitions. Therefore, we used standardized definitions to evaluate major bleeding in hospitalized patients undergoing TPE using public use data files from the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III).
-
Hemoglobin S target of <50% as compared to 30% in chronic red cell exchange for secondary stroke prevention in sickle cell disease J. Clin. Apher. (IF 1.5) Pub Date : 2023-08-01 Jihee Choi, John Emmanuel Markantonis, Nicole De Simone, Alecia Nero, Jaehyup Kim, Ravi Sarode
Sickle cell disease (SCD) patients with a history of stroke are encouraged to receive chronic red blood cell exchange (RBCx) for stroke prevention. The American Society of Hematology guideline published in 2020 recommends an HbS target of <30%. However, this approach necessitates more frequent RBCx and more RBC units. UT Southwestern has devised a chronic exchange protocol that elevates the HbS target
-
Use of subgroup-specific hematopoietic stem cell collection efficiencies to improve truncation calculations for large-volume leukapheresis procedures J. Clin. Apher. (IF 1.5) Pub Date : 2023-08-01 Kai J. Rogers, Sarah L. Mott, Meredith G. Parsons, Annette J. Schlueter
A critical component of optimizing peripheral blood (PB) hematopoietic stem cell (HSC) collections is accurately determining the processed blood volume required to collect the targeted number of HSCs. Fundamental to most truncation equations employed to determine this volume is the procedure's estimated collection efficiency (CE), which is typically applied uniformly across all HSC collections. Few
-
Prevalence of baseline hypocalcemia and symptomatic hypocalcemia during leukapheresis J. Clin. Apher. (IF 1.5) Pub Date : 2023-07-31 Kimberly Bray, Carolyn Lynde, Trizzie Vu, Amy Patterson, Richard R. Reich, Tina M. Mason, Hien D. Liu
Symptoms of hypocalcemia are reported in up to 50% of patients undergoing leukapheresis procedures. There is no set standard of practice for administering calcium supplementation in the prevention or treatment of hypocalcemia symptoms. The goal of this descriptive, retrospective study was to determine the prevalence of baseline hypocalcemia and symptomatic hypocalcemia during leukapheresis with acid
-
Botulism mimicking Guillain-Barre syndrome: The question of plasma exchange in an unusual case of acute paralysis J. Clin. Apher. (IF 1.5) Pub Date : 2023-07-30 Juan J. Silva Campos, Elizabeth Abels, Henry M. Rinder, Christopher A. Tormey, Jeremy W. Jacobs
Guillain-Barré syndrome (GBS) is an immune-mediated polyradiculoneuropathy and the most common cause of acute flaccid paralysis worldwide. GBS classically presents with acute, progressive, ascending weakness, reduced to absent reflexes, and albuminocytological dissociation on cerebrospinal fluid (CSF) analysis. Botulism is a neurotoxin-mediated acute descending flaccid paralysis with cranial nerve
-
Therapeutic leukocytapheresis for leukostasis in chronic lymphocytic leukemia: A case report and literature review J. Clin. Apher. (IF 1.5) Pub Date : 2023-07-30 Thomas Auen, Pranav Renavikar, Esther Habib, Scott A. Koepsell
Chronic lymphocytic leukemia (CLL) is a clonal mature B-cell neoplasm with a typically indolent clinical course. Though most clinicians follow these neoplasms through observation alone, an aggressive transformation to prolymphocytic leukemia, diffuse large-B-cell lymphoma (Richter transformation) or classical Hodgkin lymphoma requires immediate attention. We present a case of extreme leukocytosis (>1
-
Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation J. Clin. Apher. (IF 1.5) Pub Date : 2023-07-28 Mustafa Merter, Ugur Sahin, Osman İlhan, Meral Beksac
Adequate stem cell collection is essential for successful stem cell transplantation. Heparin enhances stem cell mobilization by competing with heparin sulfate proteoglycans. Heparin is also used as an anticoagulant before leukapheresis. Here, we evaluated the effects of heparin on stem cell mobilization in patients who underwent autologous stem cell transplantation (ASCT).
-
Development and validation of a nomogram for predicting the risk of vasovagal reactions after plasma donation J. Clin. Apher. (IF 1.5) Pub Date : 2023-07-19 Peizhe Zhao, Demei Dong, Rong Dong, Yuan Zhou, Yan Hong, Guanglin Xiao, Zhiye Li, Xuelin Su, Xingyou Zheng, Xia Liu, Demei Zhang, Ling Li, Zhong Liu
Vasovagal reactions (VVRs) are the most common adverse reactions and are frequently associated with serious donor adverse events. Even mild VVRs can lead to a significant reduction in the likelihood of subsequent donations. The purpose of this study is to explore the factors related to the occurrence of VVRs after plasma donation and to construct a nomogram to identify individuals at risk for VVRs
-
Extracorporeal photopheresis induces NETosis in neutrophils derived from patients with chronic graft-vs-host disease J. Clin. Apher. (IF 1.5) Pub Date : 2023-07-13 Idan Goldberg, Galit Granot, Alona Telerman, Shirly Partouche, Tzippy Shochat, Erez Halperin, Anat Gafter-Gvili, Liat Shargian, Moshe Yeshurun, Pia Raanani, Ofir Wolach, Vered Yahalom
Extracorporeal photopheresis (ECP) is considered an effective treatment for patients with chronic graft vs host disease (cGVHD) and demonstrates efficacy in ameliorating GVHD. The mechanism by which ECP acts against cGVHD is not fully understood. Preliminary observations have hinted at the potential involvement of neutrophil extracellular traps (NETs) formation in the pathogenesis of cGVHD. We aimed
-
Effect of extracorporeal photopheresis on survival in acute graft versus host disease J. Clin. Apher. (IF 1.5) Pub Date : 2023-07-08 Ahmet Kaya, Mehmet Ali Erkurt, İrfan Kuku, Emin Kaya, İlhami Berber, Soykan Biçim, Emine Hidayet, Salih Cırık, Süleyman Arslan, Fatma Hilal Yagın, Ahmet Sarıcı
Extracorporeal photopheresis (ECP) is the main non-pharmacological approach accompanying systemic medical treatments in steroid-resistant acute or chronic graft versus host disease. The study aimed to examine the effect of ECP on survival in acute graft versus host disease (aGVHD).
-
Efficient removal of antibodies to adeno-associated viruses by immunoadsorption J. Clin. Apher. (IF 1.5) Pub Date : 2023-07-07 Simone Boedecker-Lips, Andreas Judel, Stefan Holtz, Magnus Mayer, Pascal Klimpke, Daniel Kraus, Thomas Schreiner, Bernhard Gerstmayer, Klaus Eulitz, Magnus Christopher Mayer, Julia Weinmann-Menke
Gene therapies based on adeno-associated viruses (AAV) are a therapeutic option to successfully treat monogenetic diseases. However, the influence of pre-existing immunity to AAV can compromise the application of AAV gene therapy, most notably by the presence of neutralizing antibodies (NAb) to AAV.
-
Therapy plans for therapeutic apheresis in Epic HealthLink J. Clin. Apher. (IF 1.5) Pub Date : 2023-06-27 Vansh S. Jain, Huihua Li, Kristin P. Lee, William Nicholas Rose
A common required duty of pathology resident physicians while rotating on transfusion medicine is the medical oversight of the therapeutic apheresis service. A task often performed on this clinical medicine service is formulating and writing orders for therapeutic apheresis procedures. The EpicCare tool called the therapy plan provides unique advantages over a standard electronic order set for therapeutic
-
Why has plasma exchange failed in TRACK syndrome? Lessons from a new variant of the atypical hemolytic uremic syndrome J. Clin. Apher. (IF 1.5) Pub Date : 2023-06-20 Cansu Durak, Ebru Guney Sahin, Yasar Yusuf Can, Fatih Varol, Halit Cam
Atypical hemolytic uremic syndrome (aHUS) is a rare and life-threatening form of thrombotic microangiopathy, associated with high mortality and morbidity. Most cases present with hemolytic anemia, thrombocytopenia, and renal insufficiency. However, it can have unusual multiple end-organ injuries including extrarenal organ and system involvements such as neurologic, cardiac, gastrointestinal, and respiratory
-
A validation and modification of PLASMIC score by adjusting the criteria of mean corpuscular volume and international normalized ratio J. Clin. Apher. (IF 1.5) Pub Date : 2023-06-16 Jia-Arng Lee, Mei-Hwa Lin, Chun-Min Kang, Ming-Kai Chuang, Chi Kwan Boris Fung, Shyh-Chyi Lo
The PLASMIC score was developed for distinguishing thrombotic thrombocytopenic purpura (TTP) from other types of thrombotic microangiopathy. However, two components of the PLASMIC score, mean corpuscular volume (MCV) and international normalized ratio (INR), showed non-significant differences between TTP and non-TTP patients in previous validations. Here, we validate the PLASMIC score and aim to modify
-
A Saudi multicenter experience on therapeutic plasma exchange for patients with thrombotic thrombocytopenic purpura: A call for national registry J. Clin. Apher. (IF 1.5) Pub Date : 2023-06-15 Osman Radhwi, Maha A. Badawi, Adel Almarzouki, Fakhr Al-Ayoubi, Ghada ElGohary, Kazi Nur Asfina, Abdulrahim Mohammed Basendwah, Iman Ayed Alhazmi, Eiman A. Almahasnah, Ahmed AlBahrani, Abdulrahman Al Raizah, Ayel Yahya, Khadeja Alshahrani, Salwa Hindawi
The improvement in the clinical care for patients with thrombotic thrombocytopenic purpura (TTP) is evolving, and many efforts are being put to standardize it. Here, we aimed to assess the provided care at a national level and identify deficiencies.
-
Favorable recovery profiles and good reliability among youngest unrelated stem cell donors supports lowering the minimum donor registration age J. Clin. Apher. (IF 1.5) Pub Date : 2023-06-13 Jose Ros-Soto, Angharad Pryce, Eva Zoubek, Catherine Burlton, Richard Szydlo, Chloe Anthias
Younger donor age in hematopoietic cell transplantation has been associated with improved overall and disease-free survival. Safety data on peripheral blood stem cell (PBSC) and bone marrow (BM) donation is well established, including in the <18-year old age group in the related setting. In response, Anthony Nolan became the first stem cell donor registry to lower the minimum age for unrelated donors
-
Membrane-based therapeutic plasma exchange: Proposed techniques for preventing filter failure J. Clin. Apher. (IF 1.5) Pub Date : 2023-06-08 Ibrahim Elali, Deep Phachu, Nick Coombs, Mamta Shah, Jordan Dean, Lalarukh Haider, Yanlin Wang, Andre A Kaplan
Therapeutic plasma exchange (TPE) is commonly performed using membrane-based TPE (mTPE) and is prone to filter failure.
-
Primed for change: The effect of a blood prime on peripheral blood stem cell collection and accuracy of a prediction tool in pediatric patients J. Clin. Apher. (IF 1.5) Pub Date : 2023-05-27 Mahvish Q. Rahim, W. Scott Goebel, John Delph, Esther Soundar
Pediatric apheresis collection of peripheral blood stem cells for autologous transplantation often requires use of a blood prime. We evaluated the relationship between pre-apheresis blood CD34+ counts and final CD34+ yield with use of a blood prime. Forty patients underwent apheresis stem cell collection in a 5 year period in our hospital, of which 27 required blood priming of the apheresis machine
-
A retrospective study for association between post-transfusion hemoglobin S level and pre-transfusion hemoglobin S level at the next scheduled transfusion J. Clin. Apher. (IF 1.5) Pub Date : 2023-05-17 Ding Wen Wu, Jessica Jacobson, Mark Lifshitz, Yanhua Li, Chen Lyu, Rachel Friedmann, Ronald Walsh, Evan Himchak, Kala Mohandas, Sadiqa Karim, Etan Marks, Sang Hwa Himchak, Timothy Hilbert
Patients with sickle cell disease (SCD) frequently undergo prophylactic red blood cell (RBC) exchange transfusion and simple transfusion (RCE/T) to prevent complications of disease, such as stroke. These treatment procedures are performed with a target hemoglobin S (HbS) of ≤30%, or a goal of maintaining an HbS level of <30% immediately prior to the next transfusion. However, there is a lack of evidence-based
-
Large volume plasmapheresis using a single-use immunoadsorption column: A cost-effective approach for desensitization in ABO-incompatible liver transplant J. Clin. Apher. (IF 1.5) Pub Date : 2023-05-16 Sarika Agarwal, Ashish Maheshwari, Meenu Bajpai
Liver transplant is a life-saving treatment, but due to the limited availability of suitable liver donors, ABO-incompatible liver transplants (ABOi-LT) are conducted to increase the availability of liver donors. Perioperative desensitization for ABOi-LT is an established strategy to circumvent the risk of graft rejection. A single prolonged session can be performed to achieve the desired titers to
-
Neonatal Fc receptor blockade as emerging therapy in diseases with plasma exchange indications J. Clin. Apher. (IF 1.5) Pub Date : 2023-05-15 Muharrem Yunce, Nakul Katyal, Grace Fortes Monis, Srikanth Muppidi
Neonatal Fc receptor (FcRn) blockade may represent a mechanism similar to plasma exchange (PLEX) in reducing immunoglobulin levels and thus have a broad implication for apheresis practitioners. Although only efgartigimod received FDA approval for myasthenia gravis in December 2021, multiple trials are currently underway with different FcRn therapies in a varied group of IgG antibody-mediated neurological
-
Revisiting the benefits of isovolemic hemodilution red cell exchange for sickle cell disease J. Clin. Apher. (IF 1.5) Pub Date : 2023-04-24 Manasa S. Reddy, Ahmad Alkashash, Andrew Nord, Anne Tetrick
Isovolemic hemodilution red cell exchange (IHD-RCE) is a modified form of the standard red cell exchange (STD-RCE), intended to reduce red cell requirements in patients with sickle cell disease (SCD). This retrospective crossover analysis of nine patients aims to add to the limited existing literature on IHD-RCE and address the equipoise regarding whether the benefits of (a) decreased RBC usage per
-
Modifications to therapeutic plasma exchange to achieve rapid exchange on cardiopulmonary bypass prior to pediatric cardiac transplant J. Clin. Apher. (IF 1.5) Pub Date : 2023-04-12 Emily Davies, Sairah Khan, Yunchuan D. Mo, Cyril Jacquot, Niti Dham, Pranava Sinha, Jennifer Webb
Cardiac transplants increasingly occur following placement of ventricular assist devices (VADs). A strong association exists between human leukocyte antigen (HLA) sensitization and VAD placement; however, desensitization protocols that utilize therapeutic plasma exchange (TPE) are fraught with technical challenges and are at increased risk of adverse events. In response to increased VAD utilization
-
The efficiency of a continuous versus an intermittent apheresis method for collection of hematopoietic progenitor stem cells: A systematic review J. Clin. Apher. (IF 1.5) Pub Date : 2023-04-08 Cassandra Hobbs, Heidi Green, Ritin Fernandez
Peripheral blood hematopoietic progenitor stem cells (HPSCs) are the most common source of stem cells for autologous and allogenic transplantation. Currently, systematic reviews comparing the collection efficiency of a continuous to an intermittent method are lacking despite the existence of primary studies. Therefore, the objective of this review was to synthesize the best available evidence to compare
-
Single center experience of therapeutic plasma exchange in a resource-constrained setting: A study of trends in scope and complications J. Clin. Apher. (IF 1.5) Pub Date : 2023-04-08 Prashant Pandey, Divya Setya, Arghyadeep Marik, Shweta Ranjan, Supriya Kumari, Saikat Mandal, Praveen Kumar
Therapeutic apheresis procedures are becoming an increasingly integral part of modern medical practice, be it as a part of therapy or pre-conditioning regimes for solid organ transplants. In our center, we follow the American Society for Apheresis (ASFA) guidelines for categorizing these procedures. However, lack of a centralized registry for therapeutic apheresis in India, lack of consolidated data
-
Prospective, open-label, multicenter clinical study to assess the performance of a new donation system for the collection of source plasma J. Clin. Apher. (IF 1.5) Pub Date : 2023-04-02 Emily Mason, Kati Dawson, Jack Rhodes, James Kelley, Erin Goodhue Meyer, Toby L. Simon
Safe, efficient, and reliable innovations among donation systems are needed to meet the growing global demand for source plasma. This study assessed the ability of a new donation system to collect appropriate product weights based on the US Food and Drug Administration nomogram for source plasma collections. Procedure duration and safety endpoints were also collected.
-
Investigation on the feasibility of large-volume autologous red blood cells donation: A pilot trial in a small cohort of Chinese J. Clin. Apher. (IF 1.5) Pub Date : 2023-03-23 Jinghui Wu, Guanyi Chen, Lihua Wang, Pan Wang, Yue Han, Lei Yang, Xilin Ouyang
Preoperative autologous blood donation (PAD) is used for elective surgical procedures with a predictable blood loss. But a downward trend in PAD is due to the fact that patients with preoperative whole blood donation or two-unit red cell apheresis cannot avoid receiving allogenic blood during intensive surgery. To improve the clinical application of PAD, this study explores the feasibility of large-volume
-
Ethylene oxide-type hypersensitivity reactions in G-CSF mobilized, peripheral blood hematopoietic progenitor cell donors and review J. Clin. Apher. (IF 1.5) Pub Date : 2023-03-14 Laura Cooling, John Sherbeck
Ethylene oxide (EtO) is a volatile, ringed toxic ether used to sterilize heat-labile plastics including apheresis sets. In the 1980s, EtO-associated severe hypersensitivity reactions during hemodialysis led to widespread adoption of alternative sterilization for dialysis kits but not apheresis tubing sets. We now report several cases of EtO-type hypersensitivity reactions in autologous donors undergoing
-
Facilities, selection, outcome measurement, and limitations of therapeutic plasma exchange for neuroimmunological disorders: The South East Asian survey study J. Clin. Apher. (IF 1.5) Pub Date : 2023-03-09 Natthapon Rattanathamsakul, Sasitorn Siritho, Shanthi Viswanathan, Fu Liong Hiew, Metha Apiwattanakul, Kevin Tan, Umapathi N. Thirugnanam, Tianrong Yeo, Amy M. L. Quek, Riwanti Estiasari, Rabani Remli, Seinn Mya Mya Aye, Ohnmar Ohnmar, Nghia T. T. Hoang, Paul M. Pasco
Therapeutic plasma exchange (TPE) for neuroimmunological disorders has played an important role in the Southeast Asian region. This study investigates the challenges of performing TPE within the region.
-
Severe complications in a 25-year-old male after brown recluse spider bite treated by therapeutic plasma exchange: A case report and review of other case studies J. Clin. Apher. (IF 1.5) Pub Date : 2023-03-06 Sarah Cain, Frederick V. Plapp, Amitava Dasgupta, Zhan Ye
Although in the majority of patients (90%), the bite wound of brown recluse spider resolves spontaneously, some patients may experience a severe reaction requiring hospitalization. A 25-year-old male developed severe hemolytic anemia, jaundice, and other complications following a brown recluse spider bite on his posterior right thigh. He was treated with methylprednisolone, antibiotics, and red blood
-
Successful stem cell collection for atypical teratoid rhabdoid tumor in an extremely low-body weight child: A case report J. Clin. Apher. (IF 1.5) Pub Date : 2023-03-01 Rossana Putzulu, Alberto Romano, Aldo Mancino, Andrea Corbingi, Giuseppina Massini, Stefano Mastrangelo, Silvia Maria Pulitanò, Marco Piastra, Mauro Pittiruti, Antonio Ruggiero, Nicola Piccirillo
The use of peripheral blood hematopoietic stem cells for bone marrow reconstitution after myeloablative therapy is well established in children with malignant disorders. However, the peripheral blood hematopoietic stem cells collection in very low-body weight (≤10 kg) children remains a significant challenge because of technical and clinical issues. A male newborn affected by atypical teratoid rhabdoid
-
A nomogram prediction of citrate reaction during mononuclear cell collection in solid tumor patients J. Clin. Apher. (IF 1.5) Pub Date : 2023-02-09 Yong Xia, Hui Xue, Jing Li, Yanyan Yu, Wei Huang, Chuchu Zhou, Tingting Shi, Yanxia Cheng, Caihong Zhang, Shuang Liu, Zongchang Song, Sha Xu, Jinxing Lou
Citrate reaction is one of the main adverse events in peripheral blood mononuclear cell (MNC) collection. The aim of this study was to elucidate the risk factors for citrate reaction in patients with advanced solid tumor collection and to construct a nomogram to predict the risk.
-
Successful treatment of pure red cell aplasia using therapeutic plasma exchange after ABO-incompatible hematopoietic stem cell transplant J. Clin. Apher. (IF 1.5) Pub Date : 2023-01-26 Angelica Vivero, Alexis R. Peedin, Yuanzheng Gao, Julie Katz Karp
Hematopoietic stem cell transplants (HSCTs) are widely used in the treatment of hematologic malignancies and bone marrow failure syndromes. ABO compatibility is typically of secondary importance, and up to 50% of HSCT are performed in ABO-incompatible pairings. In the literature, pure red cell aplasia (PRCA) occurs in 1% to 50% of all major/bidirectional ABO-incompatible stem cell transplants, but